Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen has entered a research collaboration with Generate Biomedicines to develop protein therapeutics targeting five clinical indications. Amgen will provide
Amgen will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 1:00 p.m. ET. The presentation will be led by Robert A. Bradway, the CEO. The live audio will be available for public access via Amgen's website. This event underscores Amgen's commitment to addressing serious illnesses through innovative therapeutics. The webcast will also be archived for at least 90 days for those unable to attend live.
Amgen announced FDA approval for Otezla® (apremilast) to treat adults with plaque psoriasis, making it the first oral treatment approved for all severity levels. The approval stems from the Phase 3 ADVANCE trial, which showed significant efficacy, with 21.6% achieving treatment success at week 16 compared to 4.1% for placebo (p<0.0001). Otezla, which has been used by over 650,000 patients globally, offers an alternative for those inadequately managed by topical therapies. Approximately 8 million Americans suffer from plaque psoriasis, indicating a substantial market opportunity for Amgen.
Amgen has announced the FDA approval of Tezspire (tezepelumab-ekko), a first-in-class biologic for severe asthma treatment in patients aged 12 and older. This landmark approval allows it to be used without phenotypic limitations, targeting inflammation directly. Tezspire outperformed placebos in the NAVIGATOR Phase 3 trial across primary and secondary endpoints. The drug aims to aid the 34 million individuals suffering from severe asthma worldwide, offering a new treatment option for those previously inadequately addressed by existing therapies.
Amgen (NASDAQ: AMGN) announced new data from its hematology pipeline to be presented at the 63rd ASH Annual Meeting from Dec. 11-14, 2021. The data emphasizes Amgen's dedication to improving patient outcomes in blood cancers. Key presentations include updated Phase 3 trial results for BLINCYTO showing improved survival rates in children with B-ALL, and promising safety and efficacy data for subcutaneous BLINCYTO in adults. Results from the Pregnancy Surveillance Program for Nplate highlighted no significant safety concerns. Important abstracts detailing real-world outcomes in multiple myeloma will also be presented.
Amgen's Board of Directors declared a $1.94 per share dividend for Q1 2022, marking a 10% increase from the previous quarters. The dividend will be paid on March 8, 2022 to shareholders of record as of February 15, 2022. This increase reflects the company's commitment to returning value to shareholders while maintaining sustainable growth strategies. Amgen continues to focus on developing innovative therapeutics and addressing unmet medical needs in healthcare.
Amgen announced positive top-line results from the Phase 3 DISCREET trial evaluating Otezla (apremilast) for adults with moderate to severe genital psoriasis. The trial achieved significant improvement in the primary endpoint at week 16, with Otezla 30 mg twice daily showing a marked reduction in modified static Physician's Global Assessment of Genitalia scores compared to placebo. Secondary endpoints, including itch severity and body surface area involvement, also saw significant improvements. The study's adverse events aligned with Otezla's safety profile, primarily involving gastrointestinal symptoms.
Amgen (AMGN) announced the FDA approval for expanding the KYPROLIS (carfilzomib) labeling to include its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone for treating relapsed or refractory multiple myeloma in adults with one to three prior therapies. The decision is based on the Phase 2 PLEIADES study, showing an impressively high overall response rate of 84.8%. This combination aims to enhance patient convenience by reducing administration time and burden. Amgen plans to submit global marketing applications soon.
Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference on Nov. 30, 2021, at 5:10 p.m. ET. Rob Lenz, M.D., Ph.D., Amgen's Senior Vice President of Global Development, will lead the presentation, which can be accessed via a live audio webcast for media, investors, and the public. The webcast will be archived for 90 days post-event. Amgen, a biotechnology leader since 1980, focuses on innovative human therapeutics to address serious diseases and improve health outcomes for patients worldwide.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
